Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Prior treatment

• Participant who has previously failed on anti-interleukin (IL)-17 therapy;
• Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy;
• Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit;

Other illness

• Participant with known hypersensitivity to sonelokimab or any of its excipients;
• Participant with known hypersensitivity to adalimumab or any of its excipients;
• Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA;

Other

• Participant who has a diagnosis of arthritis mutilans

• Participant is ≥18 years of age;
• Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit;
• Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3);
• Participant has either current active PsO or a dermatologist confirmed history of PsO;
• Participant tests negative for rheumatoid factor (RF) at the Screening Visit;
• Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit;
• Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information.